Evidence summary: GlycanAge (Single Test)

Our Compare page lists GlycanAge (Single Test) as a glycomic test that uses a finger-prick blood sample [1]. GlycanAge says its report includes a biological age number and "glycan indexes", plus an interpretation call with a GlycanAge specialist [3]. The company also says: "GlycanAge is not a DNA or epigenetic test." [3]

The laboratory measures the sugar structures (glycans) attached to immunoglobulin G (IgG), the most common antibody in blood, and separates them into peaks [5][8]. The "biological age" comes from a formula that combines a few of these peaks [8]. That formula was originally trained to predict chronological age [8]. The published versions of the formula differ between papers [5][8]. The developers state in a 2025 paper that the commercial product uses a proprietary algorithm, and that the published formula alone returned values outside the human age range in newer data [18].

The link to inflammation is an interpretation. Research describes the age-related loss of galactose on IgG as pro-inflammatory [5][8], but the test does not measure inflammation directly.

GlycanAge (Single Test) is currently rated Emerging on Compare [1]. The rating concerns the test's own biological-age result and its association, in research populations, with chronological age and with cardiometabolic and inflammation-related markers. It does not cover measuring or monitoring an individual's inflammation, tracking one person's response to lifestyle change or treatment, predicting mortality or a specific disease, or diagnosis. This page explains that rating.

We rate GlycanAge Emerging for its own biological-age result. The research behind it is substantial: in large studies, mostly by the test's developers, an IgG glycan age tracked calendar age and was linked to metabolic and inflammation markers [8], and other laboratories have found the same age-related glycan shift [19][20]. GlycanAge calculates its result with its own formula, which is not published [18], using a different laboratory method [8][21] and a finger-prick sample [3], and in the sources we reviewed no published study has validated that result itself.

• Age signal. In 5,117 people from four European populations, an index built from three glycans explained up to 58% of the variation in chronological age in the population it was built in, and 41–48% when applied to the other three [8].
• Health links. After adjusting for age and sex, the index was associated with measures such as HbA1c, BMI and triglycerides, and with insulin in at least one of the populations [8]. These were measured at the same time, so they show association, not prediction [8].
• Outcomes. A different IgG glycan score was associated with future cardiovascular events in two clinical-trial populations [7]. This was not the GlycanAge number [7]. In the second population, adding the score barely improved prediction [7].

Under our methodology, a commercial test is rated on the evidence for its own output, not for the method behind it, and the Promising tier asks for a published method and at least one independent replication or large-cohort validation [2]. In the developers' studies we reviewed, glycans were measured in the Genos laboratory, and their authors included Genos's founder, who also co-founded GlycanAge [5][7][8]. That validation concerns the published 2014 index rather than the product's own formula [8][18]. The only published study of the commercial assay we found is the developers' precision study of the glycan measurements, not of the age result [21]. These gaps place the test at Emerging under the current criteria; a large peer-reviewed validation of the product's own result, with its method described, would support a higher rating.

GlycanAge says: "Our in-day measurement precision is ±1 year, providing the granularity needed to see the results of lifestyle interventions." [3]

None of the sources we reviewed reports the data behind this figure. Even if the figure is accurate, it describes repeat measurements on the same day [3]. Experts treat that kind of analytical precision separately from how a marker behaves in a person over time [9], so it does not tell you how much your result moves for biological reasons between tests weeks or months apart. In a secondary analysis of a randomised trial in 36 premenopausal women, suppressing ovarian hormones with medication for about five months raised glycan age by a median of about 9 years [5]. Women who also received estradiol showed no such rise, and values returned toward baseline after hormones recovered [5]. This shows that the score can shift substantially with hormonal status; the size of the shift did not track estradiol levels, and no health outcomes were measured [5]. It does not show that hormone therapy slows aging, and it is not a basis for treatment decisions [5].

The published method compares an IgG glycan pattern with patterns seen at different ages in research populations [8]. It is not a diagnosis. GlycanAge itself says such tests are not designed to predict an individual's lifespan or a specific disease [3]. Experts on aging biomarkers separate three questions: whether the lab measurement is accurate, whether the marker predicts outcomes, and whether using it improves health [9]. A 2024 review by an expert consortium notes that there is not yet agreement on how to validate aging biomarkers, and recommends a validation process that includes clinical utility [9]. The reviewed studies do not show whether using this test to guide decisions improves health.

Glycan age moves with hormonal status [5], and GlycanAge names life stages such as menopause as one influence [3]. None of the sources we reviewed gives a threshold for how large a change in one person is meaningful. Small differences between two tests should be read cautiously.

Most studies we reviewed were run in the Genos laboratory, and their authors include people with financial ties to Genos or GlycanAge [5][7][8]. A large 2026 preprint from the same laboratory reports links between faster glycan aging and mortality [17]. The archived version we checked had not been peer reviewed, and its authors include a founder of Genos and GlycanAge [17]. We treat it as exploratory, and it does not change the rating.

For current price and availability, see Compare. If you spot an error, please tell us.